A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
about
Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.Rho GTPase effectors and NAD metabolism in cancer immune suppression.The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer.
P2860
A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel orally bioavailable co ...... ve breast cancer tumor growth.
@en
A novel orally bioavailable co ...... ve breast cancer tumor growth.
@nl
type
label
A novel orally bioavailable co ...... ve breast cancer tumor growth.
@en
A novel orally bioavailable co ...... ve breast cancer tumor growth.
@nl
prefLabel
A novel orally bioavailable co ...... ve breast cancer tumor growth.
@en
A novel orally bioavailable co ...... ve breast cancer tumor growth.
@nl
P2093
P2860
P356
P1433
P1476
A novel orally bioavailable co ...... ve breast cancer tumor growth.
@en
P2093
Audrey Minden
Chetan Rane
Erkan Baloglu
Marsha Crochiere
Soumyasri Das-Gupta
William Senapedis
Yosef Landesman
P2860
P2888
P356
10.1038/SREP42555
P407
P577
2017-02-15T00:00:00Z